TB-500 (10 mg)

TB-500 from Bio-Peptide is a synthetic peptide that imitates the active part of the natural protein thymosin beta-4, which is present in almost all cells of the body. Its main task is to accelerate tissue regeneration, including muscles, ligaments, tendons and skin, as well as reduce inflammatory processes. For athletes, TB-500 is especially valuable due to its ability to quickly restore damaged tissue after intense training or injuries, improve flexibility and increase endurance, which allows you to maintain a high intensity of the training process.

This peptide is ideal for bodybuilders, athletes and other sportsmen who face connective tissue injuries or chronic inflammation. TB-500 promotes angiogenesis (growth of new blood vessels), which improves muscle nutrition and accelerates their recovery. Due to its systemic action, the peptide is effective even when administered far from the site of injury, making it convenient for use in sports practices to minimize downtime and increase productivity.

Specifications:

• is not a steroid;
• does not affect hormonal levels;
• does not have anabolic or androgenic properties;
• safe for men and women;
• a peptide that regulates actin and cell migration.

Effects of taking TB-500

1. acceleration of recovery of muscles, ligaments, joints and skin;
2. anti-inflammatory action;
3. angiogenesis: the growth of new blood vessels to improve tissue nutrition;
4. protection and restoration of the nervous system;
5. increasing joint mobility and ligament elasticity;
6. cardioprotective effect: reducing the risk of infarction and restoring the myocardium;
7. reduction of pain in case of injuries;
8. reducing fatigue and increasing endurance.

Medical indications for taking TB-500

1. injuries to muscles, ligaments, tendons and joints;
2. chronic inflammatory processes (eg, arthritis);
3. recovery from surgery or serious injuries;
4. treatment of chronic wounds, ulcers, skin lesions;
5. cardiovascular disorders (recovery after a heart attack);
6. neurological damage (for research);
7. dry eye and corneal damage (in clinical trials).

Application and dosage of TB-500

method of administration: subcutaneous (subq) or intramuscular (im);

Dosage for beginners: 2 mg/week (divide into 2-3 injections); course 4 weeks;

Dosage for advanced users: 4 mg/week (divided into 2-3 injections); course 4-5 weeks;

Dosage for professionals: 6 mg/week (divided into 2-3 injections); course 4-6 weeks;

alternative regimen: loading dose 10 mg in the first week (1–2 mg/day), then 5 mg/week (2 injections) for 5 weeks, maintenance dose 10 mg/month (2 mg every 6 days);

preparation: dilute in bacteriostatic water or 0.9% sodium chloride solution;

adviсe: injections should be given in different places, preferably on an empty stomach; after the course, maintenance therapy is possible once a month.

Side effects

• redness, irritation, or discomfort at the injection site;
• temporary fatigue or lethargy;
• headache or mild dizziness (especially when first administered);
• potential risk of increased tumor growth in the presence of oncological diseases (not proven, but requires caution);
• absence of significant side effects when dosages are followed (according to research data).

What to avoid

• exceeding recommended dosages (more than 6–10 mg/week);
• use without consulting a doctor in the presence of chronic diseases (especially oncological diseases);
• long-term use without interruption (more than 6 weeks without a break);
• incorrect dilution of the peptide (use only sterile water or saline solution);
• combinations with unknown drugs without prior interaction studies.

What other drugs will affect TB-500

compatibility: combines well with BPC-157 to enhance the regenerative effect;

synergy: may be combined with peptides such as CJC-1295 or IGF-1 to improve muscle recovery and growth (under specialist supervision);

caution: avoid taking it simultaneously with drugs that affect blood clotting without consulting a doctor;

consultation: necessary when used with medications for the treatment of cardiovascular diseases or cancer, as data on interactions are limited.